Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Cancer Genetics to Buy Gentris, a US-China Genomics CRO

publication date: Jun 23, 2014
Cancer Genetics, a diagnostics company specializing in cancer, signed a non-binding Letter of Intent to acquire Gentris Corporation, which provides pharmacogenomics, biomarker and biorepository services. Gentris is currently building a US FDA-compliant lab in Shanghai’s Zhangjiang Hi-Tech Park. The purchase price for Gentris is set at $4.75 million, comprised of $3.25 million in cash and $1.5 million in CGI stock. An additional $1.5 million of performance-based earnouts are also available. More details....

Stock Symbol: (NSDQ: CGIX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital